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Nuclear magnetic resonance (NMR) allows triglycerides (TG) to be subclassified into 14 different classes 
based on particle size and lipid content. We recently showed that these sub-fractions have differential 
associations with cardiovascular disease (CVD) events.  We report the distributions and define reference 
interval ranges for 14 TG-containing lipoprotein sub-fraction metabolites. 
 
Methods 
Lipoprotein sub-fractions using the Nightingale NMR platform were measured in 9,073 participants from 4 
cohort studies contributing to the UCL-Edinburgh-Bristol (UCLEB) consortium. The distribution of each 
metabolite was assessed. Reference interval ranges were calculated for a disease-free population, by sex and 
age group, and in participants with CVD or type 2 diabetes. We also determined the distribution across BMI 
and smoking status. 
 
Results 
The largest reference interval range was observed in the medium VLDL sub-class (2.5th 97.5th percentile; 0.08 
to 0.68 mmol/L). TG sub-fraction concentrations in VLDL, IDL, LDL and HDL sub-classes increased with 
increasing age and increasing BMI. TG sub-fraction concentrations were significantly higher in ever smokers 
compared to never smokers, among those with clinical chemistry measured total TG greater than 1.7 mmol/L, 
and in those with CVD , and type 2 diabetes as compared to disease-free subjects.  
 
Conclusion 
This is the first study to establish reference interval ranges for 14 TG-containing lipoprotein sub-fractions in 
samples from the general population measured using the NMR platform. The utility of NMR lipid measures 
may lead to greater insights for the role of TG in CVD, emphasising the importance of appropriate reference 





Risk factors for atherosclerotic disease include elevated total cholesterol, LDL-cholesterol (LDL-C) 
and triglycerides (TG), and are used in disease risk assessment in clinical care(1). Elevated TGs are common 
among people with metabolic syndrome, obesity and type 2 diabetes (T2DM)(2,3), and are associated with an 
increased risk of cardiovascular disease (CVD) (4). Population based reference intervals are used as a tool to 
define thresholds for clinical decisions. For example, clinical measurement of LDL-C for CVD risk assessment, 
which together with other measurements such as body mass index (BMI) or systolic blood pressure (SBP) can 
help to determine if lipid-lowering is indicated(5).  
 
The high-throughput proton (1H) serum nuclear magnetic resonance (NMR) metabolomics platform 
developed by Nightingale provides quantitative information on lipoprotein particle size and lipid content 
representing multiple metabolic pathways(6–8). NMR measures of lipoproteins are increasingly used in 
epidemiological and genetic studies, and may provide better insights into biological processes compared to 
clinical chemistry measures of TG, which represent the sum of all plasma TG(9).  
 
Nightingale NMR metabolomics approach has been used in two recent prospective cohort studies that 
found evidence to suggest a differential association of total serum TG and TG sub-fractions with coronary heart 
disease (CHD) (10,11). For example, total serum TG association with CHD was OR 1.19 (95% CI 1.10 to 
1.28), TG in the VLDL sub-fractions was associated with CHD in the range of OR 1.12 to 1.22, whereas TG in 
the LDL sub-fractions conveyed a relatively lower risk (OR in the range 1.13 to 1.17) (11). The different 
associations of 14 TG-subfractions with CHD highlight the need to extend the standard lipid reference intervals 
to include lipid lipoprotein sub-fractions. 
In the present study we aim to define reference intervals for 14 TG-containing lipoprotein sub-fraction 
metabolites (TG sub-fractions) using data from multiple UK based cohorts from the UCLEB consortium.  
 
Methods 
Population study sample 
We sourced data from the UCL-Edinburgh-Bristol (UCLEB) consortium, including NMR metabolite 
measures in 9,073 participants from 4 cohort studies: The British Regional Heart Study (BRHS), including men 
aged 60-79 at assessment in 1998-2000, the Whitehall II study (WHII), including UK government workers 




study including British men and women from European (SABRE1), South Asian (SABRE2) and African 
Caribbean (SABRE3) descent, and the Caerphilly Prospective Study (CAPS), including men registered in 
general practice aged 55-69 at assessment in 1989-1993. The design and data collection for the UCLEB 
Consortium of longitudinal population studies has been described previously(12). Age (years), sex 
(male/female), smoking (ever/never), body mass index (BMI), CHD, stroke and T2DM variables were 
collected at the time of NMR blood sample measurement.  
 
Metabolite quantification 
Using Nightingale NMR metabolomics platform(8), high-throughput metabolite quantification of 14 
TG containing lipoprotein sub-fractions (mmol/L) were ascertained in fasting and non-fasting serum samples in 
all contributing studies. To ensure long-term sample integrity, blood samples were stored and transported at -80 
°C across all contributing UCLEB studies until NMR quantification in 2014. NMR metabolomics platform has 
been extensively used in epidemiology and genetics studies(13–15), and its application reviewed and described 
in detail elsewhere(6,16).  
 
Statistical analysis 
We removed individuals based on any event of CHD, stroke or T2DM to include a healthy, ‘disease 
free’ population. We first assessed the study-specific distribution of each 14 TG sub-fraction and then pooled 
individual participant data form all four cohorts into one dataset. Reference intervals were based on the 2.5th, 
and 97.5th percentiles stratified by age and sex. Age group bands were calculated as <55 years, 55-65 years and 
>65 years. The influence of fasting, age, smoking and BMI on the sub-fraction distributions were assessed 
statistically and graphically using “generalised linear model” (GAM) curves, Kolmogorov–Smirnov (KS) test, 
and using box plots. Reference intervals were additionally calculated in the following groups; 1) participants 
with CVD (defined as occurrence of either CHD or stroke, 2) participants with T2DM, 3) participants with 




A total of 9,073 individuals were included in the main healthy, free of CVD and type 2 diabetes study 
sample, of which 5,574 (62.8%) were male (median age 61.7 years, IQR  52.0, 67.6) who had median BMI of 




median age of 53.9 (IQR 49.9, 59.9), a BMI of  25.6 (23.6, 27.8) kg/m2 and 431 (13.0%) were ever smokers. 
Description of study population and median concentration of 14 sub-fractions is shown in table 1. 
 
We compared the sum of TG in the 14 sub-fractions to clinical chemistry measured total TG and 
found an increase of 0.34 mmol/L of NMR measured total TG for every 1 mmol/L increase in clinical 
chemistry measured total TG ([insert supplementary Figure 1]). The overall study population distribution for 
the 14 TG sub-fractions were comparable across contributing studies, showed agreement between ethnicities in 
the SABRE cohort ([insert supplementary Figure 2]) and overlap of TG measured in the fasting and non-
fasting state ([insert supplementary Figure 3]). Of the 14 TG sub-fractions, 12 had a skewed right tailed 
distribution, and two (medium and small HDL) had a more symmetrical distribution.  
 
The reference intervals (2.5th – 97.5th) percentile for 14 TG sub-fractions are shown in ([insert table 
2]) and graphically in ([insert figure 1]). Wide reference intervals were observed in the VLDL subclass, for 
example the reference interval for TG in medium VLDL and small VLDL was, 0.08-0.67 mmol/L and 0.10-
0.46 mmol/L, respectively. A smaller reference interval range was observed for TG in IDL, LDL and HDL 
subclass sub-fractions, for example, the reference interval range for TG in large HDL was 0.01-0.05 mmol/L. 
 
Subgroup reference interval ranges 
Age and sex stratified reference interval ranges for 14 TG metabolites are presented in ([insert 
supplementary Table 2]). Reference interval ranges (2.5th-97.5th percentile) were comparable between men 
and women across metabolites. For example, among men aged <55 years, the large VLDL reference interval 
was in the range 0.01 – 0.24 mmol/L, and for women of the same age band the reference interval range was 
0.02-0.03 mmol/L.  
 
([Insert figure 2]) shows GAM curves and density distribution for the sum of VLDL, IDL, LDL and 
HDL subclass sub-fractions for age and BMI, and box plot for TG distribution by smoking status. Among men, 
TG concentration increased with age, with the most prominent age differences observed in the HDL subclass 
(figure 3, left panel). By comparison, TG concentration differences were not as noticeable for women for whom 
concentrations were comparable for the VLDL, IDL, LDL and HDL subclasses by age. For both men and 




subclasses. Ever smokers had higher mean TG sub-fraction concentrations across all subclasses as compared to 
never smokers. 
 
In the disease subgroups that were removed from all previous analyses reported above, the reference 
interval ranges for 14 sub-fractions were comparable between those with CVD (N = 2719 and those with 
T2DM (N = 1325). In general, the largest variation in reference interval ranges across the sub-fractions 
between these sub-groups was observed in the VLDL subclass ([insert supplementary Table 3]). For 
example, the 2.5th to 97.5th  reference interval range for TG in medium VLDL in CVD: 0.09, 0.79 mmol/L and 
in T2DM: 0.08, 0.84 mmol/L.  
 
The reference interval ranges across 14 TG sub-fractions were comparable in TG measured in the 
fasting and non-fasting state and were higher in the group with clinical chemistry measured total TG greater 
than 1.7mmol/L as compared to less than 1.7mmol/L, see ([insert supplementary Table 3].  
 
Discussion 
This study provides reference interval ranges for TG in 14 lipoprotein sub-fraction metabolites as 
measured by NMR spectroscopy based on a sample of UK adults. There was agreement in the distribution of 
triglyceride sub-fraction concentrations between ethnicities. Triglyceride concentrations for men and women 
increase with increasing age and BMI, are higher among ever smokers and in those with CVD and T2DM as 
compared to disease-free subjects, and in individuals with total TG concentrations greater than 1.7 mmol/L. 
 
Lipid reference interval ranges are derived using clinical chemistry measurement of blood samples 
from a reference population and are necessary to enable clinicians to apply analytical data in healthcare 
delivery. For example, clinical chemistry estimates of LDL-C are measured in individuals and evaluated 
against an interval range to inform lifestyle or therapeutic intervention for CHD prevention. The role of TG in 
CHD risk is less clear. Meta-analysis from prospective observational studies has demonstrated higher 
concentrations of clinical chemistry measured total TG are associated with higher risk of CHD, but effect 
estimates attenuate to the null after adjustment for HDL-C (17). On the other hand, Mendelian randomisation 
studies support a potential causal association for TG (18). The association of the major blood lipid fractions 
(LDL-C, TG and HDL-C) with CHD is seen across the whole of the concentration range,  with no threshold 




report should not therefore be taken to imply that individuals whose measurements lie within these ranges are 
free of CHD risk. Rather we simply report the observed values in general UK populations. 
NMR methodology offers the potential for more granular quantification of TG in different lipoproteins 
that would otherwise be unavailable using conventional approaches, enabling a more detailed investigation of 
TG-containing lipoprotein sub-fractions in relation CHD risk and prognosis. Evidence from studies using this 
approach suggest CHD risk may be divergent depending on the type of lipoprotein sub-fraction. Two recent 
studies report observations of TG in VLDL sub-fractions may be more atherogenic and associated with a higher 
risk of CHD compared to TG in the IDL, LDL and HDL subclass sub-fractions(10,11).  
 
This study evaluates the concentration distribution and range of TG in 14 sub-fractions and includes 
data from multiple UK population cohorts and from men and women from a range of age groups and ethnicities 
including European, South Asian and African-Caribbean ancestry. We compare total TG measured using 
clinical chemistry and the sum of NMR TG across the 14 sub-fractions. Discrepancies between clinical 
chemistry methods and NMR measured total TG have been reported previously(10,17). In one such study, 
Balling, 2019(17) suggests differences in analytical calibration from measurement of TGs between the two 
methods may lead to measurement differences, with NMR quantification deemed as the more accurate 
method(18). TG concentrations are variable and, in addition to age, sex and ethnicity, can depend on factors 
such as food intake, fasting/non-fasting state, CVD and metabolic disorders such as type 2 diabetes(19). Due to 
the relatively large sample sizes available, we observed a significant difference between the fasting and non-
fasting distribution of sub-fractions. This significant difference did not prove relevant for determining the 
reference interval ranges, which were comparable to 2 decimal points. Moreover, it is postulated the non-
fasting state predominates the 24-hour cycle due to varying food intake patterns, and mean changes of +0.3 
mmol/L from baseline TG measures do not translate to clinically significant differences. Higher TG 
concentrations are observed in post-menopausal vs pre-menopausal women(20). We report comparable TG 
concentrations across age groups, however, it is possible a greater difference in TG concentration may be 
observed in a larger sample of women aged >65 than are included here. Due to small numbers of current 
smokers in the available data across the contributing cohorts we stratified by ever and never smoking status, 
instead of the more informative  “never”, “ex“ and “current” smokers. We exclude participants with current 
CVD or T2DM in the main analyses, however it is possible TG levels in the study population were altered by 




TG monitoring is likely to occur in individuals at risk of, or with current CVD. Therefore, we provide 
additional reference intervals in participants with CVD and T2D.  
 
We establish reference interval ranges of 14 TG-containing lipoprotein sub-fractions for men and 
women by age, BMI, smoking status, CVD, T2DM and stratified by clinical chemistry measured total TG and 
fasting status for population-based cohorts from the UK population. Further studies would be needed to assess 
if the reference intervals presented here could be extended to a non-UK population and if the risks associated 
with the reference intervals identify a threshold within these ranges to inform CVD risk in a clinical setting. By 
doing so, the reference interval ranges may help to set realistic targets and guide research interests, contributing 
to the development of effective targeted TG lowering therapies, aimed at for example VLDL sub-fractions 
which may be the most atherogenic(10). NMR lipoprotein particle number and size have been assessed in 
relation to CHD, however this study specifically presents reference range intervals for TG within the 14 sub-
fractions(21). Further investigations would be needed to compare sub-fraction lipid composition, particle 
number concentration and size.  
 
Metabolomics is becoming integrated with genomics to contribute to a better understanding of disease 
aetiologies and disease risk(22). It is likely that quantitative metabolomics will be incorporated into large 
biobanks, which would extend the relevance of sample collection and encourage the life-long assessment of 
metabolic health(6).  TG sub-fraction reference interval ranges may help complement current routine clinical 
chemistry measures of lipids and become an integral tool in targeted patient management and improved disease 
risk prediction and prevention.  
 
Conclusion 
This study is the first to establish reference interval ranges for 14 triglyceride containing lipoprotein 
sub-fraction metabolites, measured using the Nightingale NMR platform for men and women in a UK 
population. NMR measures of lipoproteins may provide insights into biological processes compared to clinical 
chemistry measures of TG and lead to greater insights for the role of TG in CVD, emphasising the importance 
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